Pharming Group N.V. (PHGUF)

Pharming Group N.V. (PHGUF) Healthcare & Pipeline Overview

Pharming Group N.V. is a biopharmaceutical firm focused on developing and commercializing protein replacement therapies and precision medicines for rare diseases and critical unmet medical needs. Its portfolio includes Ruconest for hereditary angioedema and a pipeline targeting various conditions, supported by strategic collaborations in the US, Europe, and other international markets.

What Is the Investment Thesis for PHGUF?

Pharming Group N.V. presents a focused investment thesis centered on its established rare disease therapy, Ruconest, and a diversified pipeline targeting significant unmet medical needs. The company's financial profile, characterized by an 88.1% gross margin and 3.3% profit margin, demonstrates efficient operations in its core commercialized product. With a market capitalization of $833.38M, Pharming is positioned within the specialized biotechnology sector. Key value drivers include the continued global expansion and market penetration of Ruconest for hereditary angioedema, leveraging its orphan drug designation for market exclusivity. Growth catalysts are primarily driven by the advancement of its pipeline assets, particularly leniolisib for activated PI3K delta syndrome, and the broader applications of rhC1INH in conditions like pre-eclampsia and acute kidney injury. Strategic collaborations, such as those with Novartis and Orchard Therapeutics for OTL-105, further enhance its development capabilities and potential market reach. Investors will evaluate the company's ability to navigate regulatory pathways for these rare disease treatments and successfully commercialize new therapies, building on its existing infrastructure and expertise in specialized markets.

Based on FMP financials and quantitative analysis

PHGUF Key Highlights

• Gross Margin of 88.1% indicates strong profitability on product sales, significantly above many industry averages.
• Profit Margin of 3.3% reflects the company's ability to generate net income from its revenue, despite ongoing R&D investments typical for a biopharmaceutical firm.
• Return on Equity (ROE) of 5.0% demonstrates the company's efficiency in generating profits from shareholders' equity.
• Debt-to-Equity (D/E) ratio of 43.20 suggests a moderate reliance on debt financing relative to equity, providing financial flexibility.
• Market Capitalization of $833.38M positions Pharming as a mid-cap biopharmaceutical company focused on niche markets.

Who Are PHGUF's Competitors?

PHGUF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHGUF's Key Strengths?

• Flagship product Ruconest for hereditary angioedema with established market presence.
• High gross margin of 88.1% indicating strong product profitability.
• Diversified pipeline targeting multiple rare diseases and unmet medical needs.
• Strategic collaborations with major pharmaceutical companies like Novartis and Orchard Therapeutics.

What Are PHGUF's Weaknesses?

• Reliance on a single primary commercialized product (Ruconest) for a significant portion of revenue.
• Relatively low profit margin of 3.3% for a biopharmaceutical company, potentially reflecting R&D intensity.
• Exposure to the high-risk, long-cycle nature of drug development and regulatory approvals.
• Trading on the OTC Other tier, which can imply lower liquidity and less stringent reporting.

What Could Drive PHGUF Stock Higher?

• Regulatory milestones for leniolisib in activated PI3K delta syndrome, including potential marketing authorization applications or approvals in key regions.
• Clinical trial readouts or advancements for rhC1INH in new indications such as pre-eclampsia, acute kidney injury, or COVID-19, which could expand its therapeutic utility.
• Progress in the strategic alliance with Orchard Therapeutics plc for OTL-105, including initiation of later-stage clinical trials or data presentations for the gene therapy for hereditary angioedema.
• Continued global commercial expansion and market penetration of Ruconest for hereditary angioedema, driving sustained revenue growth.
• Development updates or clinical progress for the alpha-glucosidase therapy targeting Pompe and Fabry diseases, moving these assets closer to potential commercialization.

What Are the Key Risks for PHGUF?

• Inconsistent delivery — missed Wall Street EPS estimates in 3 of the last 8 reported quarters.
• Clinical trial failures or unexpected adverse events for pipeline candidates, leading to delays or discontinuation of development programs.
• Intense competition in the rare disease space, potentially impacting market share and pricing power for existing and future products.
• Regulatory hurdles and potential non-approval of new therapies by health authorities like the FDA or EMA, delaying or preventing market entry.
• Dependence on the commercial success of Ruconest, making the company vulnerable to market shifts or increased competition in the hereditary angioedema segment.
• Risks associated with trading on the OTC Other tier, including lower liquidity, wider bid-ask spreads, and less stringent reporting requirements, which can affect investor confidence and share valuation.

What Are the Growth Opportunities for PHGUF?

• Expansion of Ruconest Indications and Geographic Reach: Ruconest, Pharming's flagship product for hereditary angioedema, holds significant potential for expanded market penetration and potential new indications. While currently approved for acute HAE attacks, further research or label extensions could broaden its use. The global market for HAE treatments is substantial, driven by increasing diagnosis rates and demand for effective therapies. Pharming's established commercial infrastructure in the US and Europe provides a solid foundation for continued sales growth and potential entry into new international territories, leveraging its existing regulatory approvals and distribution networks.
• Advancement of rhC1INH Pipeline: The recombinant human C1 esterase inhibitor (rhC1INH) platform, beyond Ruconest, represents a key growth driver. Pharming is actively exploring rhC1INH for pre-eclampsia, acute kidney injury, and COVID-19. Pre-eclampsia affects a significant portion of pregnancies globally, while acute kidney injury is a common and serious complication in hospitalized patients. Successful clinical development and regulatory approval in these larger patient populations could unlock substantial new revenue streams, diversifying the company's reliance on HAE. The timelines for these developments are typically multi-year, involving rigorous clinical trials.
• Commercialization of Leniolisib for APDS: Leniolisib, a PI3K delta inhibitor, is being developed for activated PI3K delta syndrome (APDS), a rare primary immunodeficiency. APDS patients currently have limited treatment options, indicating a high unmet medical need. The orphan drug designation often associated with such rare disease therapies can provide market exclusivity and expedited regulatory pathways. Successful approval and commercial launch of leniolisib would establish Pharming in another specialized therapeutic area, leveraging its expertise in rare disease commercialization. The market for APDS treatments, while niche, commands premium pricing due to the severity and rarity of the condition.
• Development of Alpha-Glucosidase Therapy: Pharming's pipeline includes an alpha-glucosidase therapy aimed at treating Pompe and Fabry diseases, both severe lysosomal storage disorders. These conditions require lifelong enzyme replacement therapies, representing a consistent and high-value market. The global market for lysosomal storage disorder treatments is projected to grow, driven by increasing awareness and diagnostic capabilities. Developing a competitive alpha-glucosidase therapy could position Pharming to capture a share of this established market, potentially offering improved efficacy or safety profiles over existing treatments, thereby providing a significant long-term revenue opportunity.
• Strategic Alliance with Orchard Therapeutics for OTL-105: The collaboration with Orchard Therapeutics plc on OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for hereditary angioedema, represents a cutting-edge growth opportunity. Gene therapies hold the promise of potentially curative treatments for genetic disorders, commanding high value. This alliance allows Pharming to participate in the advanced gene therapy space without bearing the full R&D burden independently. Successful development and commercialization of OTL-105 could establish Pharming as a leader in innovative HAE treatments, potentially redefining the standard of care and securing a significant market position in the long term.

What Opportunities Does PHGUF Have?

• Successful expansion of rhC1INH into new indications like pre-eclampsia, acute kidney injury, and COVID-19.
• Regulatory approval and commercialization of leniolisib for activated PI3K delta syndrome.
• Advancement of alpha-glucosidase therapy for Pompe and Fabry diseases.
• Potential for OTL-105 gene therapy to redefine hereditary angioedema treatment.
• Geographic expansion of existing and future products into new international markets.

What Threats Does PHGUF Face?

• Clinical trial failures or delays for pipeline products.
• Intense competition from other biopharmaceutical companies in rare disease markets.
• Regulatory hurdles and potential non-approval of new therapies.
• Pricing pressures and reimbursement challenges for high-cost rare disease treatments.
• Patent expirations or emergence of biosimilars for Ruconest.

What Are PHGUF's Competitive Advantages?

• Orphan Drug Designations: Therapies for rare diseases often receive orphan drug status, granting market exclusivity for a period post-approval, protecting against generic competition.
• Specialized Therapeutic Focus: Expertise in protein replacement therapies and precision medicines for rare diseases creates a niche market where competition is less broad than in common ailments.
• Proprietary rhC1INH Platform: The genetically engineered human C1 esterase inhibitor (Ruconest and pipeline) represents a proprietary technology with potential for multiple indications.
• Established Commercial Infrastructure: A global commercial presence for Ruconest in the US and Europe provides an existing network for launching new rare disease products.
• Strategic Collaborations: Partnerships with companies like Novartis and Orchard Therapeutics provide access to additional R&D capabilities, funding, and potential market reach for complex therapies.

What Does PHGUF Do?

Pharming Group N.V. operates as a biopharmaceutical firm dedicated to the creation and commercialization of innovative protein replacement therapies and precision medicines. Headquartered in Leiden, the Netherlands, the company has established a global presence, reaching patients across the United States, Europe, and other international regions. Pharming's core mission revolves around addressing rare diseases and areas characterized by significant unmet medical needs, striving to deliver life-changing treatments to patient populations often overlooked by broader pharmaceutical development. The company's flagship therapeutic product is Ruconest, a genetically engineered human C1 esterase inhibitor. Ruconest is specifically designed and approved for the management of acute episodes associated with hereditary angioedema (HAE), a rare and potentially life-threatening genetic condition. Beyond this foundational product, Pharming maintains a robust and active development pipeline, exploring the broader therapeutic potential of its recombinant human C1 esterase inhibitor (rhC1INH). This includes investigations into its efficacy for conditions such as pre-eclampsia, a severe pregnancy complication; acute kidney injury, a critical medical emergency; and as a potential treatment for certain aspects of COVID-19. Further diversifying its therapeutic portfolio, Pharming is actively developing leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) inhibitor. This novel compound is aimed at individuals diagnosed with activated PI3K delta syndrome (APDS), another rare primary immunodeficiency. The company is also advancing an alpha-glucosidase therapy, targeting the lysosomal storage disorders Pompe and Fabry diseases. Pharming's strategic approach extends to collaborative partnerships, notably a development and licensing collaboration with Novartis, a global pharmaceutical leader. Additionally, a strategic alliance with Orchard Therapeutics plc focuses on the research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy also aimed at treating hereditary angioedema. This comprehensive strategy underscores Pharming's commitment to innovation and addressing a wide spectrum of rare and challenging medical conditions.

What Products and Services Does PHGUF Offer?

• Develops and commercializes protein replacement therapies for rare diseases.
• Focuses on precision medicines for critical unmet medical needs.
• Markets Ruconest, a C1 esterase inhibitor for hereditary angioedema (HAE) in the US, Europe, and other regions.
• Investigates rhC1INH for new indications including pre-eclampsia, acute kidney injury, and COVID-19.
• Develops leniolisib for activated PI3K delta syndrome (APDS).
• Researches alpha-glucosidase therapy for Pompe and Fabry diseases.
• Engages in development and licensing collaborations, such as with Novartis.
• Partners with Orchard Therapeutics on OTL-105, a gene therapy for HAE.

How Does PHGUF Make Money?

• Generates revenue primarily through the sale of its commercialized therapeutic product, Ruconest, for hereditary angioedema.
• Secures licensing fees and milestone payments from development collaborations with pharmaceutical partners like Novartis.
• Aims to commercialize new pipeline products, such as leniolisib, upon successful regulatory approval, thereby expanding its product portfolio and revenue streams.
• Leverages orphan drug designations for its rare disease therapies to gain market exclusivity and premium pricing.
• Engages in strategic alliances to share development costs and risks for advanced therapies like gene therapy.

What Industry Does PHGUF Operate In?

Pharming Group N.V. operates within the highly specialized and competitive biotechnology industry, specifically targeting the rare disease and precision medicine segments. This sector is characterized by high R&D costs, lengthy regulatory approval processes, and the potential for significant market exclusivity through orphan drug designations. Global trends indicate a growing focus on personalized medicine and therapies for rare conditions, driven by scientific advancements and increasing patient advocacy. Pharming's flagship product, Ruconest, positions it directly in the hereditary angioedema market, competing with other C1 esterase inhibitors. Its pipeline, addressing conditions like activated PI3K delta syndrome, Pompe, and Fabry diseases, places it among companies developing therapies for distinct genetic disorders. The industry landscape includes both large pharmaceutical companies with rare disease divisions and smaller, specialized biotechs. Pharming differentiates itself through its proprietary rhC1INH platform and strategic collaborations, aiming to capture market share in these high-value, underserved therapeutic areas.

Who Are PHGUF's Key Customers?

• Patients suffering from hereditary angioedema (HAE) who require treatment for acute attacks.
• Individuals diagnosed with activated PI3K delta syndrome (APDS) seeking targeted therapies.
• Patients with lysosomal storage disorders such as Pompe and Fabry diseases, requiring enzyme replacement therapies.
• Healthcare providers, including specialists in immunology, hematology, and rare diseases, who prescribe and administer these specialized treatments.
• Hospitals and clinics that manage patients with complex and rare medical conditions.

Company Profile

Pharming Group N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Leiden, NL. The company is led by CEO Fabrice Chouraqui. PHGUF has traded publicly since 2002.

Pharming Group N.V. Financial Trajectory

Pharming Group N.V. (PHGUF) reported $71.5M in revenue for Q1 2026, a decline of 33.4% compared to the prior quarter. The company recorded a net loss of $5.1M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PHGUF averaged $0.00 in diluted EPS.

How Pharming Group N.V. Is Valued

Pharming Group N.V. carries a market capitalization of $833.38M, placing it in the small-cap category. Relative to its peer group, PHGUF's quantitative score of 63/100 is below the peer average of 76/100.

ROE 5%Key Financial Metrics

Return on equity for Pharming Group N.V. stands at 4.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. PHGUF trades at a trailing price-to-earnings ratio of 77.80, above the Healthcare sector average of ~23x. Its free cash flow yield is 5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.63 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Pharming Group N.V.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.79 places it in the grey zone, a middle ground that warrants monitoring.

3/8 beatsEarnings Track Record

Pharming Group N.V. has missed Wall Street's EPS estimate in 3 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1003.6% below estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Pharming Group N.V. revenue of about $403.5M for fiscal 2026, with EPS near $0.02. The estimate reflects 4 contributing analysts.

PHGUF Financials

PHGUF Latest News

PHGUF Analyst Consensus

PHGUF MoonshotScore

PHGUF Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources